We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 93.00
Bid: 92.00
Ask: 94.00
Change: 0.50 (0.54%)
Spread: 2.00 (2.174%)
Open: 93.00
High: 93.50
Low: 92.50
Prev. Close: 92.50
CNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

12 Apr 2021 07:00

RNS Number : 0558V
Concurrent Technologies PLC
12 April 2021
 

This announcement contains inside information

12 April 2021

Concurrent Technologies Plc

 

Results for the year ended 31 December 2020

 

Concurrent Technologies Plc (AIM: CNC), a world leading specialist in the design and manufacture of high-end embedded computer boards for critical applications, announces results for the year to 31 December 2020.

 

Financial Highlights

· Revenue for the year increased 9% to £21.1m (2019: £19.4m)

· Gross profit increased 12% to £11.4m (2019: £10.2m)

· Gross margin increased to 53.7% (2019: 52.7%)

· EBITDA steady at £5.0m (2019: £5.1m)

· Adjusted Profit before tax of £2.8m (2019: 3.1m after adjusting for other, non-recurring income of £1.0m)

· Profit before Tax of £2.8m (2019: £4.1m - including other, non-recurring income of £1.0m)

· Profit after Tax of £2.7m (2019: £4.0m)

· Adjusted EPS for 2020 was 3.75 (2019: 4.38 after removing the non-recurring income of £1m and the associated tax impact)

· Dividend increased to 2.55 pence per share for the year (2019: 2.50 pence)

· Cash in the business increased to £11.8m (2019: £10.5m)

 

Operational Highlights

 

· Production and the design and development functions have remained open and, for the most part, fully operational throughout the COVID-19 pandemic. The Group has not participated in any government aid scheme such as the Coronavirus Business Interruption Loan Scheme (CBILS) or VAT payment deferral and no employees have been furloughed during the pandemic.

· Exports remain strong and contribute 91% of Group revenue

· Cessation of R&D facility in India almost completed and functions transferred to UK. Costs of cessation were £0.7m which have been recognised in the 2020 accounts.

· Spending on R&D increased to £3.89m in 2020 (2019: £3.51m), of which £1.88m was capitalised (2019: £2.26m).

 

The Group's previous Chairman, Michael Collins, retired from the Board in September 2020 after 31 years' service to the Group. Mike's knowledge and experience helped to guide the Group from start-up to PLC. Mark Cubitt was appointed as the Group's new Chairman at the AGM, having previously joined the Board as a Non-Executive Director in March 2020. Mark is a Chartered Accountant and is a member of the Association of Corporate Treasurers. He has extensive multinational experience gained over the last 33 years, including 23 years in the listed PLC environment. 

 

Mark Cubitt, Chairman of Concurrent Technologies Plc, commented:

 

"During 2020, the Group introduced several new high-performance embedded computer boards and accessory modules. These included products based on the 9th generation embedded Intel® Xeon® processor for use in AMC, CompactPCI® and OpenVPX™ architectures.

As part of the Group's long-term continuous improvement strategy, and to mitigate an identified risk to the business during 2020, a further investment of £155,000 was made within manufacturing to introduce a new circuit board processing line.

The Board is taking a cautious approach to revenue growth in the coming year because of the continuing uncertainty caused by the COVID-19 outbreak and the delays seen to some programmes potentially moving revenue from 2021 to 2022. However, the Group's proven ability to adapt to the challenges brought about by the pandemic, the overhead savings from closure of the Indian design office, its ability to provide a well-supported, UK designed and manufactured product, and the current record order book, which has seen a substantial increase during the first quarter of 2021, gives the Board confidence in the Group's continuing solid performance."

 

Annual General Meeting

 

Due to the COVID-19 crisis and social distancing requirements the date and arrangements for the AGM will be announced separately.

 

Enquiries:

Concurrent Technologies PlcJane Annear, Managing Director/CEO

 

+44 (0)1206 752626

Newgate (Financial PR)Bob Huxford

Isabelle Smurfit

 

+44 (0)20 7653 9848+44 (0)20 7653 3411

Cenkos Securities Plc (NOMAD)Neil McDonald

Peter Lynch

+44 (0)131 220 9771

+44 (0)131 220 9772

 

Extracts from the Strategic Report

Review of Operations

The Group generated record Revenue for the year of £21.14m (2019: £19.38m). This converted into Gross Profit of £11.36m (2020: £10.21m) while the gross margin improved to 53.7% (2019: 52.7%).

Profit before tax was £2.85m (2019: £4.06m: 2019 included other, non-recurring income of £1.0m). Earnings per share was 3.75 pence (2019: 5.51 pence) while earnings per share on normal activities, adjusted to remove the impact of Other Income, was 3.75 pence (2019: 4.38 pence). EBITDA (measured as Operating Profit plus Depreciation and Amortisation) for the Group in 2020 was £4.99m (2019: £5.07m).

The Group continued its long-term commitment to R&D by spending £3.89m in 2020 (2019: £3.51m), of which £1.88m was capitalised (2019: £2.26m) and £0.69m related to closure costs of the Indian R&D centre. In light of the slowdown in the sales of some projects, an unusually large impairment charge of £888,579 (2019: £483,630) was included during the year to reflect relatively pessimistic cash generating expectations of itemised projects.

The Group continues to have no borrowings and again paid increased dividends during the year. Its cash balances plus short to medium term cash deposits at the year-end were £11.8m (2019: £10.5m).

 

Operational Highlights 

During 2020, the Group introduced several new high-performance embedded computer boards and accessory modules. These included products based on the 9th generation embedded Intel® Xeon® processor for use in AMC, CompactPCI® and OpenVPX™ architectures. These products were introduced as part of the Group's policy to provide existing customers with products that can be used as upgrade paths from previous generations where additional processing power or enhanced features are required. New customers benefit from choosing products based on the latest technologies. As required by many applications, these new products offer support for enhanced security features and most are suitable for both commercial and harsh environments. In addition, support for additional partner software and hardware products was announced to broaden the Group's product range. The Group's AI technology product is currently being developed for use on a prototype third-party end product that may come to market this year.

As part of the Group's long-term continuous improvement strategy, and to mitigate an identified risk to the business during 2020, a further investment of £155,000 was made within manufacturing to introduce a new circuit board processing line. This line will significantly help to reduce lead times for particular product variants.

 

Outlook

The new financial year of 2021 started with a healthy order book which has seen a significant increase during the first quarter of the year. The Group's telecoms business is now recovering and growing after last year's second half slow down, and several customers in the defence and telecoms sectors have placed orders for previous generation products that have been offered under extended manufacturing to protect and extend the lifecycle of their projects. These orders are due for delivery in 2021 and beyond. Several of the Group's customers have made the decision to upgrade to its newer generation products.

The Group plans to maintain its policy of investing in R&D to expand its current range of advanced technology products with a particular focus on the OpenVPX™ bus architecture, featuring the latest Intel processors suitable for the long lifecycle embedded markets in which the Group operates. Support for third party software and hardware products will be continued in order to enhance the Group's capability to provide development systems. These ready-to-use development systems enable customers to reduce their product development times by focussing on their own areas of expertise to develop specialised applications.

The Board sees opportunities to grow the business organically by broadening the range of both hardware and software products within its existing core markets of defence and telecommunications. Savings made from ceasing operations in the Indian office will largely be reinvested to increase and broaden the skills and technical expertise within the UK team. In addition, the Board continues to look to recruit key individuals and skill for both succession and organic growth as well as for worldwide acquisition opportunities which would assist the Group in introducing new skills and technologies complementary and adjacent to its current product ranges. This is with the aim of increasing the Group's potential share of the total available market.

 

Dividend

The Board has declared a second interim dividend of 1.45 pence per share (2019: 1.45 pence) which, when added to the first interim dividend of 1.10 pence per share (2019: 1.05 pence), will make a total of 2.55 pence per share for the year (2019: 2.50 pence). This is an increase of 2.0% on dividends paid for 2019. The total cost of this second interim dividend amounts to £1,063,771. As in previous years, the Directors do not intend to recommend a final dividend.

 

Annual General Meeting

Due to the COVID-19 crisis and social distancing requirements the date and arrangements for the AGM will be announced separately.

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

Consolidated Statement of Comprehensive Income

Year to

Year to

31 December

31 December

2020

2019

CONTINUING OPERATIONS

£

£

Revenue

21,141,294

19,384,724

Cost of sales

9,780,750

9,174,588

Gross profit

11,360,544

10,210,136

Operating expenses

8,444,962

7,204,073

Group operating profit

2,915,582

3,006,063

Finance costs

(83,985)

(41,808)

Finance income

16,480

96,601

Other Income

-

1,000,000

Profit before tax

2,848,077

4,060,856

Tax

98,167

52,857

Profit for the year

2,749,910

4,007,999

Other Comprehensive Income

Items that will be reclassified subsequently to profit or loss:

Exchange differences on translating foreign operations

(283,681)

(186,972)

Tax relating to components of other comprehensive income

-

-

Other Comprehensive Income for the year, net of tax

(283,681)

(186,972)

Total Comprehensive Income for the year

2,466,229

3,821,026

Profit for the period attributable to:

Equity holders of the parent

2,749,910

4,007,999

Total Comprehensive Income attributable to:

Equity holders of the parent

2,466,229

3,821,026

Earnings per share

Basic earnings per share

3.75p

5.51p

Diluted earnings per share

3.74p

5.47p

 

Consolidated Balance Sheet

As at

As at

31 December

31 December

2020

2019

(as restated)

£

£

ASSETS

Non-current assets

Property, plant and equipment

1,734,965

1,638,429

Intangible assets

7,205,581

7,991,119

Deferred tax assets

134,775

142,894

9,075,321

9,772,442

Current assets

Inventories

5,533,574

5,097,907

Trade and other receivables

2,356,157

2,703,960

Current tax assets

305,113

274,221

Other financial assets

-

-

Cash and cash equivalents

11,765,974

10,487,902

19,960,818

18,563,990

Total assets

29,036,139

28,336,432

LIABILITIES

Non-current liabilities

Deferred tax liabilities

1,571,830

1,453,331

Trade and other payables

704,800

838,001

Long term provisions

16,162

16,731

2,292,792

2,308,063

Current liabilities

Trade and other payables

4,143,522

4,126,823

Short term provisions

16,354

16,832

Current Tax Liabilities

26,504

-

4,186,380

4,142,655

Total liabilities

6,479,172

6,451,718

Net assets

22,556,967

21,884,714

EQUITY

Capital and reserves

Share capital

739,000

739,000

Share premium account

3,699,105

3,699,105

Capital redemption reserve

256,976

256,976

Cumulative translation reserve

(121,293)

162,388

Profit and loss account

17,983,179

17,027,245

Equity attributable to equity holders of the parent

22,556,967

21,884,714

Total equity

22,556,967

21,884,714

 

Consolidated Cash Flow Statement

Year to

Year to

31 December

31 December

2020

2019

£

£

Cash flows from operating activities

Profit before tax for the period

2,848,077

4,060,856

Adjustments for:

Finance income

(16,480)

(96,601)

Finance costs

83,985

41,808

Depreciation

282,563

315,687

Amortisation

1,793,628

1,788,003

Impairment loss

888,579

483,630

Share-based payment

6,991

82,421

Exchange differences

(300,569)

(205,790)

Decrease/(increase) in inventories

(435,667)

(1,001,331)

(Increase)/decrease in trade and other receivables

347,803

648,621

Increase/(decrease) in trade and other payables

(9,354)

1,232,237

Cash generated from operations

5,489,557

7,349,541

Tax received

40,536

(21,173)

Net cash generated from operating activities

5,530,092

7,328,368

Cash flows from investing activities

Interest received

16,480

96,601

Purchases of property, plant and equipment (PPE)

(385,964)

(476,376)

Capitalisation of development costs and purchases of intangible assets

(1,896,659)

(2,272,054)

Net cash used in investing activities

(2,266,143)

(2,651,829)

Cash flows from financing activities

Equity dividends paid

(1,864,968)

(1,745,345)

Repayment of leasing liabilities

(108,195)

(108,426)

Interest paid

(83,985)

(41,808)

Sale of treasury shares

47,529

4,950

Net cash used in financing activities

(2,009,619)

(1,890,629)

Effects of exchange rate changes on cash and cash equivalents

23,742

22,640

Net increase/(decrease) in cash

1,278,072

2,808,550

Cash at beginning of period

10,487,902

7,679,352

Cash at the end of the period

11,765,974

10,487,902

 

 

Consolidated Statement of Changes in Equity

Capital

Cumulative

Profit

Share

Share

redemption

translation

and loss

Total

capital

premium

reserve

reserve

account

Equity

£

£

£

£

£

£

Balance at 1 January 2019

739,000

 3,699,105

256,976

349,360

14,670,553

19,714,994

Profit for the period

-

-

-

-

4,007,999

4,007,999

Exchange differences on translating foreign operations

-

-

-

(186,972)

-

(186,972)

Total comprehensive income for the period

-

-

-

(186,972)

4,007,999

3,821,027

Transactions with owners:

Share-based payment

-

-

-

-

82,421

82,421

Deferred tax on share based payment

-

-

-

-

6,667

6,667

Dividends paid

-

-

-

-

(1,745,345)

(1,745,345)

Purchase of treasury shares

-

-

-

-

4,950

4,950

Balance at 31 December 2019

739,000

3,699,105

256,976

162,388

17,027,245

21,884,714

Profit for the period

-

-

-

-

2,749,910

2,749,910

Exchange differences on translating foreign operations

-

-

-

(283,681)

-

(283,681)

Total comprehensive income for the period

-

-

-

(283,681)

2,749,910

2,466,229

Transactions with owners:

Share-based payment

-

-

-

-

6,991

6,991

Deferred tax on share based payment

-

-

-

-

16,472

16,472

Dividends paid

-

-

-

-

(1,864,968)

(1,864,968)

Sale of treasury shares

-

-

-

-

47,529

47,529

Balance at 31 December 2020

739,000

3,699,105

256,976

(121,293)

17,983,179

22,556,967

NOTES

 

1. The Group financial statements consolidate those of the Company and its subsidiaries (together referred to as the 'Group'). The financial information set out in these preliminary results has been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006. The accounting policies adopted in this results announcement have been consistently applied to all the years presented. The restatement of balance sheet items refers to lease liabilities which have been reclassified from current to non-current liabilities. The adjustment does not impact shareholder funds or profit previously stated.

 

2. The financial information set out above does not constitute the Group's statutory accounts for the years ended 31 December 2020 or 2019, but is derived from those accounts. Statutory accounts for 2019 have been delivered to the Registrar of Companies and those for 2020 will be delivered following the Annual General Meeting. The auditors have reported on those accounts; their reports were (i) unqualified, (ii) did not contain statements under section 498(2) or (3) of the Companies Act 2006 in respect of 2019 or 2020 and (iii) did not draw attention to any matters by way of emphasis.

 

3. The calculation of basic earnings per share is based on the weighted average number of Ordinary Shares in issue during 2020 of 73,253,120 (2019: 72,724,271) after adjustment for treasury shares on the profit after tax for 2020 of £2,749,910 (2019: £4,007,999). The calculation of diluted earnings per share incorporates 311,651 Ordinary Shares (2019: 574,542) in respect of performance related employee share options. The profit after tax is the same as for basic earnings per share.

 

4. Due to the COVID-19 crisis and social distancing requirements the date and arrangements for the AGM will be announced separately.

 

Copies of the Annual Report will be sent to Shareholders and will also be available from the Company's Registered Office: 4, Gilberd Court, Newcomen Way, Colchester, Essex, CO4 9WN, UK, and on the Company's website: www.gocct.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR EANLEFLPFEFA
Date   Source Headline
24th Apr 20247:00 amRNSUS Contract Win and Notice of Results
9th Apr 20247:00 amRNSNew Product Announcement
5th Feb 20247:00 amRNSBoard Appointment
17th Jan 20247:00 amRNSTrading update
21st Dec 20237:00 amRNSKey VME Contract Win
19th Dec 20231:07 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSTrading Update
9th Nov 20237:00 amRNSNew Product Announcement
8th Nov 20237:00 amRNSChange of Nominated Adviser
7th Nov 20237:00 amRNSAppointment of New Auditors
2nd Nov 20237:00 amRNSHolding(s) in Company
24th Oct 20237:00 amRNSDirector/PDMR Dealing - Issue of Share Options
28th Sep 20237:00 amRNSNew Product Announcement
19th Sep 20237:00 amRNSInterim Results
6th Sep 20237:00 amRNSAcquisition of Phillips Aerospace
5th Sep 202312:04 pmRNSHolding(s) in Company
5th Sep 20237:00 amRNSNotice of Results
4th Sep 20231:20 pmRNSResult of General Meeting
25th Aug 20237:00 amRNSResult of Retail Offer
24th Aug 20233:07 pmRNSResult of AGM
16th Aug 20237:05 amRNSRetail Offer for up to £0.3 million
16th Aug 20237:00 amRNSProposed Acquisition and Notice of General Meeting
11th Aug 20233:15 pmRNSHolding(s) in Company
8th Aug 20237:00 amRNSNew Product Announcement
1st Aug 202310:58 amRNSNew Product Announcement
20th Jul 20237:00 amRNSNotification of Major Holdings
18th Jul 20237:00 amRNSPosting of Annual Report and Notice of AGM
17th Jul 20237:00 amRNSPost-Close Trading Update
30th Jun 20237:00 amRNSResults for the year ended 31 December 2022
19th Jun 20237:00 amRNSUpdate on Audited Annual Results
12th Jun 20237:00 amRNSSignificant Systems Win
9th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20237:00 amRNSNew Distributor Agreement
5th Jun 20237:00 amRNSNotice of Results
24th Mar 20237:00 amRNSNew Product Announcement
21st Mar 20237:00 amRNSReseller Agreement
4th Jan 20237:00 amRNSPost-Close Trading Update
14th Dec 20227:00 amRNSPartnership Agreement
28th Oct 20227:00 amRNSIssue of Share options and PDMR dealing
5th Oct 20227:00 amRNSConcurrent Technologies Enters the Systems Market
26th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
24th Aug 202210:29 amRNSHolding(s) in Company
24th Aug 202210:27 amRNSHolding(s) in Company
19th Aug 202212:06 pmRNSHolding(s) in Company
13th Jul 20227:00 amRNSSupply Agreement
29th Jun 202212:55 pmRNSResult of AGM
30th May 20227:00 amRNSPosting of Annual Report & Notice of AGM
23rd May 20222:46 pmRNSIssue of Share options and PDMR dealing
12th May 20227:00 amRNSResults for the year ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.